Therapeutic Asset Ratings

705 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Breyanzi Injectable Product Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Dordaviprone Glioblastoma	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
HUMAN CULTURE EXPANDED GENETICALLY MODIFIED AUTOLOGOUS T CELLS FOR CELL-BASED GENE THERAPY. CELLS ARE DERIVED FROM ISOLATED BLOOD OF THE PATIENT AND ARE TRANSDUCED WITH NON-REPLICATIVE SELF-INACTIVATING (SIN) HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) BASED LENTIVIRAL VECTOR (LVV) PSEUDOTYPED WITH THE VESICULAR STOMATITIS VIRUS GLYCOPROTEIN G (VSV-G) ENVELOPE PROTEIN, AND ENCODING THE C11D5.3 ANTI-TNF RECEPTOR SUPERFAMILY MEMBER 17 (TNFRSF17, BCMA) SINGLE CHAIN VARIABLE FRAGMENT (SCFV) CD8/4-1BB/CD3ZETA CHIMERIC ANTIGEN RECEPTOR (CAR) UNDER THE TRANSCRIPTIONAL CONTROL OF THE MYELOPROLIFERATIVE SARCOMA VIRUS ENHANCER, NEGATIVE CONTROL REGION DELETED, DL587REV PRIMER-BINDING SITE SUBSTITUTED (MND) PROMOTE Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Mgta-456 Hodgkins Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Mgta-456 Mantle Cell Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Oral Restorative Microbiota Therapy Lung Cancer	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Adaptnk Acute Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P1/2	CCC (48)
Allogeneic Car19 Regulatory T Cells Hematopoietic And Lymphoid System Neoplasm	Masonic Cancer Center, University of Minnesota	P1/2	CCC (48)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Acute Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P2	CC (46)
Mgta-456 Acute Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P2	CC (46)
Cyclophosphamide Monocytic Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (46)
DARATUMUMAB Monocytic Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (46)
Fludarabine Monocytic Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (46)
LISPRO-PH20 COMPONENT RHUPH20 Monocytic Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (46)
Bortezomib Li-Fraumeni Syndrome	Masonic Cancer Center, University of Minnesota	P1/2	CC (45)
Cpx-351 Li-Fraumeni Syndrome	Masonic Cancer Center, University of Minnesota	P1/2	CC (45)
DARATUMUMAB Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (44)
LISPRO-PH20 COMPONENT RHUPH20 Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (44)
ft536 Astrocytic Tumor	Masonic Cancer Center, University of Minnesota	P1	CC (43)
ft536 Primary Peritoneal Carcinoma	Masonic Cancer Center, University of Minnesota	P1	CC (43)
ft536 Progressive Disease	Masonic Cancer Center, University of Minnesota	P1	CC (43)
Gtb-360 Myeloid Neoplasm	Masonic Cancer Center, University of Minnesota	P1	CC (43)
Vic-1911 Myeloproliferative Neoplasm	Masonic Cancer Center, University of Minnesota	P1/2	CC (43)
Vic-1911 Acute Leukemia	Masonic Cancer Center, University of Minnesota	P1/2	CC (42)
Enoblituzumab Peritoneum Cancer	Masonic Cancer Center, University of Minnesota	P1	CC (41)

Showing 576 to 600 of 705 assets

PreviousPage 24 of 29Next